Modulation of trophoblast function by concurrent hyperglycemia and antiphospholipid antibodies is in part...

Area of Science:

• Reproductive immunology
• Maternal-fetal medicine
• Endocrinology

Background:

• Diabetes and antiphospholipid syndrome (APS) individually increase risks for poor perinatal outcomes, particularly preeclampsia.
• Concurrent antiphospholipid antibodies (aPL) and diabetes are linked to heightened pregnancy morbidity.
• Both hyperglycemia and aPL independently induce pro-inflammatory, anti-angiogenic, and anti-migratory responses in human trophoblasts.

Purpose of the Study:

• To investigate the combined effects of hyperglycemia and aPL on human first-trimester extravillous trophoblast function.
• To elucidate the molecular mechanisms underlying trophoblast dysfunction under concurrent hyperglycemic and aPL conditions.

Main Methods:

• Human first-trimester extravillous trophoblast cells were exposed to normoglycemic or hyperglycemic conditions with or without low-dose aPL.
• Measurements included inflammatory cytokines (IL-1β, IL-8), angiogenic factors (PlGF, sFlt-1, sEndoglin), inflammasome components (uric acid, caspase-1), and trophoblast migration.
• TLR4 antagonist was used in specific experimental groups.

Main Results:

• Concurrent excess glucose and aPL significantly augmented IL-1β, uric acid, caspase-1, and PlGF compared to excess glucose alone.
• This combination also dampened IL-8, sEndoglin, and sFlt-1 levels.
• Trophoblast migration was further reduced under combined hyperglycemia and aPL exposure.

Conclusions:

• Concurrent aPL and hyperglycemia exert detrimental effects on trophoblast function.
• The simultaneous presence of these two insults elicits some paradoxical protective responses.
• Findings underscore the complex interplay between metabolic and autoimmune factors in pregnancy complications.